Novartis cancer med combats lymphoma

The Novartis kidney-cancer remedy Afinitor cut tumor size by 50 percent or more in a third of lymphoma patients in a mid-stage trial; the Swiss drugmaker has started a late-stage trial to evaluate disease-free survival in patients with that disease. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.